The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer

Thyroid

Volumn 19, Issue 8, 2009, Pages 811-813

  McDougall, I Ross ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

CANCER RISK; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; LUNG METASTASIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; THYROID CANCER; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINES AS TOPIC; HUMANS; IODINE RADIOISOTOPES; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASMS; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 68349084407     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.1582     Document Type: Editorial

References (17)

1. Spies W, Wojtowicz CH, Spies SH, Shah AY, Zimmer AM 1989 Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 14:793-800. (Pubitemid 20020131)
2. Park H-M, Perkins OW, Edmondson JW, Schnute RB, Manatunga A 1994 Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49-54. (Pubitemid 24145887)
3. Park H, Park YH, Zhou XH 1997 Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7:277-280. (Pubitemid 27190596)
4. McDougall IR 1997 74MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 18:505-512.
5. Silberstein EB 2007 Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 48: 1043-1046.
6. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA 2007 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 92:28-38. (Pubitemid 46075005)
7. Bal CS, Kumar A, Pant GS 2004 Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89:1666-1673. (Pubitemid 38507919)
8. 131I ablation in patients with welldifferentiated thyroid cancer. Thyroid 19:849-855.
9. de Vathaire F 2008 The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:180-181.
10. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Jondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644. (Pubitemid 37464133)
11. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819-1825.
12. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451-457.
13. Brzozowska M, Roach PJ 2006 Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series. Clin Nucl Med 31:683-687. (Pubitemid 44624553)
14. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
15. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
16. Perros P CS, Franklin J, Gerrard G, Harrison B, Hickey J, Kendall-Taylor P, McNicol AM, Mallick UK, Prentice M, Thakker RV, Watkinson J, Weetman AP. Guidelines for the Management of Thyroid Cancer. Second edition. Lavenham Press, Royal College of Physicians of London, 2007, p 18.
17. Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, Mandel SJ 2007 Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 34:1012-1017. (Pubitemid 46919552)